Periodic Reporting for period 1 - OVAL (The OVAL study for VB-111 treatment of platinum-resistant ovarian cancer)

VBL therapeutics is a late-stage clinical biopharmaceutical company focused on first in class treatments for cancer. VBL's lead oncology product candidate, VB-111, is an innovative targeted anti-cancer gene therapy with potential to treat a wide range of solid tumors. Most...